Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5565 | Ordered by Date (descending)
next pagenext page 1 2 3 4 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Carrick Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 4.29% of voting rights 2019-12-31
Celmatix–Evotec: investment, 201912 investment existent Evotec owns 25.02% of voting rights 2019-12-31
Eternygen–Evotec: investment, 201912 investment existent Evotec owns 24.97% of voting rights 2019-12-31
Exscientia–Evotec: investment, 201912 investment existent Evotec owns 23.21% of voting rights 2019-12-31
Fibrocor Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 16% of voting rights of Fibrocor LLP 2019-12-31
Forge Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights 2019-12-31
FSHD Unlimited Coop–Evotec: investment, 201912 investment existent Evotec owns 21.12% of voting rights 2019-12-31
Immunitas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 6.44% of voting rights 2019-12-31
Topas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 28.44% of voting rights 2019-12-31
Provecs–NONE: investment, 201912–202001 bankruptcy AG Hamburg 67g IN 290/19 insolvency + dissolution Provecs Medical GmbH 2019-12-30
Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc 2019-12-20
Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors 2019-12-20
CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance 2019-12-19
Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies 2019-12-19
Kinnate Biopharma–Nextech: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd 2019-12-19
Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman 2019-12-19
Promega–Merck (DE): CRISPR technology, 201912– license to CRISPR IP io from Merck to Promega to develop CRISPR-edited cell lines 2019-12-19
BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi 2019-12-18
Novartis–Voluntis: digital therapeutics, 201912–collab developm digital therapeutics using Theraxium Oncology platform for breast cancer 2019-12-18
BioNtech–EU (govt): credit, 201912– EIB/EFSI loan €50m to support cancer therapies r+d 2019-12-17
Cellestia Biotech–SEVERAL: investment, 201912 financing round Series B CHF20m from FC Capital + PPF Group + Partners Investment + private investors 2019-12-17
Resistell–SEVERAL: investment, 201912 financing round Series A CHF3.5m 2019-12-17
3SBio–Numab: antibody cancer drug, 201912– collab developm + commercialisation with Sunshine Guojian for multi-specific Abs in Greater China 2019-12-12
Numab–3SBio: investment, 201912–202003 financing round Series B totalling CHF22m incl CHF15m from new investor 3SBio/Sunshine Guojian 2019-12-12
Numab–Eisai: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Eisai Co Ltd 2019-12-12
Numab–Mitsubishi: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Mitsubishi UFJ Capital Co Ltd 2019-12-12
Numab–PERSON: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Daniel Vasella 2019-12-12
Numab–SEVERAL: investment, 201912–202003 financing round Series B CHF22m incl €15m from new investor 3SBio/Sunhine Guojian 2019-12-12
Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) 2019-12-10
ImmunOs Therapeutics–SEVERAL: investment, 201912 financing round Series CHF15m co-led by Pfizer Ventures + BioMedPartners 2019-12-10
Schauenburg–JP Scientific: SPE technology, 201912– ww commercial license + supply to Markes from JP Scientific Ltd 2019-12-10
Algiax Pharmaceuticals–SEVERAL: investment, 201912 financing round €5.5m incl new investor Occident 2019-12-09
EMBL–Bruker: microscope, 201912 supply existent early customer EMBL for new Luxendo TruLive3D Imager 2019-12-09
Synthorx–Sanofi: investment, 201912– acquisition $2.35b cash tender offer at $68/share ANNOUNCED 2019-12-09
BC Platforms–Scius Communications: public relations, 201912 supply service existent by Scius Communications 2019-12-06
Life & Brain–BC Platforms: genomic software tools, 201912– collab using BC Platforms solutions for genotyping services 2019-12-06
4Teen4 Pharmaceuticals–Brandenburg (govt): investment, 201912 financing round Series A totalling €6.9m incl lead investor Brandenkapital GmbH 2019-12-05
4Teen4 Pharmaceuticals–SEVERAL: investment, 201912 financing round Series A €6.9m led by Brandenkapital GmbH with private investors + business angels 2019-12-05
Biological Industries (IL)–Sartorius: investment, 201912 acquisition of just over 50% for €45m in cash with option to acquire further 20% 2019-12-05
ImCheck Therapeutics–Dentons: legal services, 201912 supply service Dentons Europe acted as legal counsel for €48m Series B round of ImCheck 2019-12-04
ImCheck Therapeutics–SEVERAL: investment, 201912 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures 2019-12-04
ImCheck Therapeutics–Trophic Communications: public relations, 201912 service existent IR + PR US + EU by Trophic 2019-12-04
ImCheck Therapeutics–Wellington Partners: investment, 201912 financing round Series B totalling €48m incl new + co-investor Wellington Partners 2019-12-04
Indivumed–Biognosys: MS-based proteomics, 201912– collab integration of HRM MS proteomics data into multi-omics IndivuType cancer database 2019-12-02
Innate Pharma–Rentschler: biologics contract manufacturing, –201912 supply service production lacutamab for clinical trials 2019-12-02
Novartis–Oxford BioMedica: lentiviral vector technology, 201912– supply agreem extension for 5y 2019-12-01
ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB 2019-11-29
ViGeneron–MC Services: public relations, 201911 service existent media + investor relations by MC Services 2019-11-28
ViGeneron–Sequoia Capital: investment, 201911 financing round Series A incl co-lead investor Sequoia Capital China 2019-11-28
ViGeneron–SEVERAL: investment, 201911 financing round Series A co-led by WuXi AppTec + Sequoia Capital China 2019-11-28
ViGeneron–WuXi PharmaTech: investment, 201911 financing round Series A incl co-lead investor WuXi AppTec 2019-11-28
MaxiVax–EU (govt): grant, 201911 Horizon 2020 EIC Accelerator grant €2.785m 2019-11-26
MaxiVax–SEVERAL: investment, 201911 financing round Series B2 CHF5m from existing + new investors 2019-11-26
Single Use Support–SHS: investment, 201911 investment by SHS Gesellschaft für Beteiligungsmanagement within framework of capital increase 2019-11-26
Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec 2019-11-25
Medicines Company–Novartis: investment, 201911– cash tender offer $9.7b at $85/share ANNOUNCED 2019-11-24
Immunitas Therapeutics–Bayer: investment, 201911 financing round Series A totalling $39m incl co-lead investor Leaps by Bayer 2019-11-21
Immunitas Therapeutics–Evotec: investment, 201911 financing round Series A totalling $39m incl co-investor Evotec 2019-11-21
Immunitas Therapeutics–Merck (DE): investment, 201911 financing round Series A totalling $39m incl co-investor M Ventures 2019-11-21
Immunitas Therapeutics–Novartis: investment, 201911 financing round Series A totalling $39m incl co-lead investor Novartis Venture Fund 2019-11-21
Immunitas Therapeutics–SEVERAL: investment, 201911 financing round Series A $39m co-led by Leaps by Bayer + Novartis Venture Fund 2019-11-21
LabCorp–Qiagen: bioinformatics, 201911– license extension with HGMD in addition ot Qiagen Clinical Insights 2019-11-20
Causaly–SEVERAL: investment, 201911 financing round Series A $5m led by Pentech Ventures + incl EBRD VC + Marathon VC et al. 2019-11-19
CRISPR Therapeutics–SEVERAL: investment, 201911–201912 public offering $315.25m with 4.25m+637.5k common shares at $64.5/share 2019-11-19
Kuros–SEVERAL: investment, 201911–201912 capital increase CHF12.5m with 6.405m new registered shares at CHF1.95/share 2019-11-19
Novartis–Causaly: Natural Language Processing s/w, 201911 collab existent 2019-11-19
Rodin Therapeutics–Alkermes: investment, 201911 acquisition $100m upfront cash + $850m milestones by Alkermes 2019-11-18
Turbine–Atlantic Labs: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Atlantic Labs Manager GmbH 2019-11-13
Turbine–Delin Ventures: investment, 201911 first institutional financing round totalling €3m incl lead investor Delin Ventures 2019-11-13
Turbine–o2h: investment, 201911 first institutional financing round totalling €3m incl new + co-investor o2h Ventures 2019-11-13
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Esther Dyson 2019-11-13
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Vishal Gulati 2019-11-13
Turbine–SEVERAL: investment, 201911 first institutional financing round €3m led by Delin Ventures + incl Atlantic Labs et al. 2019-11-13
Evotec–Merck (DE): CRISPR technology, 201911– license to CRISPR IP portfolio from Merck to Evotec 2019-11-12
Immatics–Genedata: bioinformatics, 201911– license to Genedata Biologics for use with Xceptor TCR discovery + engineering platform 2019-11-12
NEC–Vaximm: cancer vaccines, 201911– collab + option agreem for personalised neoantigen cancer vaccines 2019-11-12
Vaximm–NEC: investment, 201911 equity investment by NEC in connection with collab + option agreem 2019-11-12
Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED 2019-11-11
eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer 2019-11-07
eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures 2019-11-07
eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures 2019-11-07
eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners 2019-11-07
Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform 2019-11-07
Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA 2019-11-06
Vifor Pharma–Evotec: drug r+d, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w 2019-11-06
Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners 2019-11-04
Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners 2019-11-04
Saniva Diagnostics–Xlife Sciences: investment, 201911 investment by Xlife Sciences AG in Saniva Diagnostics GmbH 2019-11-04
Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma 2019-10-31
AstraZeneca–BBG/Braun Group: quetiapine fumarate, 201910– acquisition $178m upfront + up to $61m rights to Seroquel/XR in Europe + RU by Cheplapharm 2019-10-30
Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market 2019-10-28
OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m 2019-10-23
MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion 2019-10-22
MCG Motion Capture–Biotech Alliances International: investment banking, 201910– service excl for planned $15m Series A Round of MCG 2019-10-22
next pagenext page 1 2 3 4 ... 54 55 56  next pagenext page



Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top